Clinical TrialJul 14, 2026, 09:17 AM
Biogen Advances Diranersen to Phase 3 After Positive Phase 2 Data
AI Summary
Biogen announced positive Phase 2 CELIA study data for diranersen, an investigational tau-targeting therapy for early Alzheimer's disease. The study demonstrated meaningful clinical efficacy, with the 60 mg dose showing significant slowing of cognitive decline (e.g., 42% on ADAS-Cog13, 50% on MMSE, 26% on CDR-SB), and robust biomarker effects, including 50-65% reduction in CSF total tau. Despite not meeting the primary endpoint for dose response, the consistent evidence supports advancing diranersen to confirmatory Phase 3 development. The therapy was generally well tolerated and previously received FDA Fast Track designation.
Key Highlights
- Biogen to advance diranersen into confirmatory Phase 3 development.
- 60 mg dose showed 42% slowing on ADAS-Cog13 and 50% on MMSE.
- 60 mg dose demonstrated 26% slowing on CDR-SB at 18 months.
- Diranersen reduced CSF total tau by 50-65% across all doses.
- First tau-directed therapy to show reductions in CSF total tau and brain tau pathology.
- Phase 2 CELIA study did not meet primary endpoint for dose response.
- Diranersen received FDA Fast Track designation in 2025.
Price Impact
More from BIIB